Quarterly report pursuant to Section 13 or 15(d)

ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)

v3.21.1
ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)
Aug. 19, 2019
USD ($)
WSU License Agreement [Member]  
Reimbursement of patent expenses $ 75,000
Percentage of third party royalties payable for reduction in royalties payable 50.00%
Maximum percentage reduction of royalties payable 50.00%
Contingent milestone payment obligation $ 3,400,000
Asset Purchase Agreement [Member] | TRImaran Pharma Inc [Member]  
Payment for purchase of assets 100,000
Liabilities assumed 68,500
Achievement payments payable $ 3,400,000